Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Hemab Therapeutics
Denmark
- Copenhagen, Capital Region
- 22/02/2023
- Series B
- $135,000,000
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
- Industry Biotechnology Research
- Website https://hemab.com/
- LinkedIn https://www.linkedin.com/company/hemabaps/
Related People
Benny SorensenFounder
United States -
Cambridge, Massachusetts
Experienced patient centric Biotechnology Executive with demonstrated translational research, early- intermediate- and late stage clinical development experience. Strong entrepreneurial profile and successful track record of building lean high-performing R&D organizations. Excellent presentation and discussion skills. Extensive pharma-, biotech- and clinical academic high profile network.
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)